Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.
暂无分享,去创建一个
Jeffrey E. Lee | A. Maitra | I. Wistuba | Huamin Wang | R. Wolff | Yanqing Huang | M. Katz | Michael P. Kim | C. Tzeng | Jun Zhao | L. Prakash | L. Soto | Hua Wang
[1] S. Jalkanen,et al. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer , 2020, Virchows Archiv.
[2] J. Bowser,et al. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers , 2020, Frontiers in Immunology.
[3] D. Pe’er,et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma , 2019, Nature Medicine.
[4] P. Ascierto,et al. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer , 2019, Virchows Archiv.
[5] J. Bergh,et al. CD73 Immune Checkpoint Defines Regulatory NK-cells within the Tumor Microenvironment. , 2019, The Journal of clinical investigation.
[6] M. Oyama,et al. CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts , 2019, BMC Cancer.
[7] D. Allard,et al. Targeting the adenosine pathway for cancer immunotherapy. , 2019, Seminars in immunology.
[8] Liangjing Zhou,et al. The distinct role of CD73 in the progression of pancreatic cancer , 2019, Journal of Molecular Medicine.
[9] C. Iacobuzio-Donahue,et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.
[10] C. Sempoux,et al. CD73 expression in normal and pathological human hepatobiliopancreatic tissues , 2019, Cancer Immunology, Immunotherapy.
[11] P. Boström,et al. Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer , 2018, Carcinogenesis.
[12] R. Salgia,et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.
[13] C. Sotiriou,et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Jeffrey E. Lee,et al. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy , 2017, Pancreas.
[15] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[16] Adam A. Margolin,et al. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.
[17] K. Olive,et al. Current and Emerging Therapies in Metastatic Pancreatic Cancer , 2017, Clinical Cancer Research.
[18] H. Sugimura,et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer , 2017, Oncotarget.
[19] T. Ji,et al. CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma , 2016, Oncology letters.
[20] R. Broaddus,et al. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. , 2015, The Journal of clinical investigation.
[21] Deena M. A. Gendoo,et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. , 2015, Cancer research.
[22] T. Hermanns,et al. CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer , 2015, Disease markers.
[23] F. Saad,et al. CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer , 2015, Clinical Cancer Research.
[24] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[25] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[26] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[27] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.
[28] Bin Zhang,et al. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma , 2015, Tumor Biology.
[29] S. Loi,et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.
[30] R. Vonderheide,et al. Inflammatory networks and immune surveillance of pancreatic carcinoma. , 2013, Current opinion in immunology.
[31] Yitian Chen,et al. Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. , 2013, World journal of gastroenterology.
[32] Jung-Hye Choi,et al. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration , 2012, Journal of gynecologic oncology.
[33] Xiaojian Wu,et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer , 2012, Journal of surgical oncology.
[34] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[35] H. Arakawa,et al. Current Immunotherapeutic Approaches in Pancreatic Cancer , 2011, Clinical & developmental immunology.
[36] S. Jalkanen,et al. Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression , 2011, European journal of immunology.
[37] M. Smyth,et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.
[38] S. Rosenberg,et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.
[39] C. Compton,et al. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.
[40] Carmen Drahl. NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE: AWARDS: Three win for work on telomere biochemistry , 2009 .
[41] S. Colgan,et al. Physiological roles for ecto-5’-nucleotidase (CD73) , 2006, Purinergic Signalling.
[42] S. Colgan,et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.
[43] A. Ohta,et al. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.
[44] V. Natarajan,et al. [The Nobel Prize in physiology or medicine]. , 1998, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[45] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.